National Cancer Prevention and Early Detection Month
April marks National Cancer Prevention and Early Detection Month - a time to emphasize the critical role early detection of cancer plays in improving therapeutic outcomes and survival rates. At @GenEndeavor, we're dedicated to advancing our mission of creating diagnostic tools for the early detection of ovarian cancer. We are uniting a consortium of global partners who share our vision for developing an accessible diagnostic tool specifically tailored for early detection of ovarian cancer. Let's join forces to drive meaningful progress in the battle against ovarian cancer!
Radio Interview with Ricardo Mancebo
Radio interview with GenEndeavor Founder & CEO Ricardo Mancebo at the BIO CEO & Investor Conference in New York City that aired on March 11, 2024. Courtesy of "Community Matters" Host, Jonjy Ananth and Co-host, Uma Ananth
Alina Nalyvayko joins GenEndeavor!
GenEndeavor is delighted to announce the addition of Alina Nalyvayko to our team! Previously, Alina served as a Staff Research Associate at the Department of Experimental Medicine at UCSF and brings her expertise in Molecular Biology and m.TB research to GENENDEAVOR LLC to explore and advance accessible diagnostic solutions for TB patients.
GenEndeavor to attend the BIO-Europe Spring Conference, March 19, 2024
We are thrilled to announce @GenEndeavor will be presenting at the upcoming BIO-Europe Spring Conference in Barcelona, Spain on March 19, 2024.
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.
Brindhi Amalraj joins GenEndeavor
"Joining GenEndeavor fills me with excitement as I look forward to immersing myself in molecular diagnostics and making significant contributions to tackling practical challenges." - Brindhi Amalraj
GenEndeavor attending the BIO CEO & Investor Conference, NY 2/26 & 2/27
We are thrilled to announce @GenEndeavor’s participation in the upcoming BIO CEO & Investor Conference, in New York City, NY, on February 26-27, 2024.
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.
Commitment to Early Detection: Chris Evert’s story
Despite some incredible progress made in cancer research in the last several years, sadly, advanced stage ovarian cancer still results in a 17% survival rate. This means that there are no screening tests available for the nearly 4 billion women in the world.
Year-end thoughts
As we approach the end of the year, we at @GenEndeavor continue to think about the challenges that persist in women's healthcare. Despite some incredible progress made in cancer research, sadly, advanced stage ovarian cancer still results in a 17% survival rate.
GENENDEAVOR presents at the MedInvest Oncology Investor conference
It was my pleasure to present GenEndeavor’s approach to developing an early-detection ovarian cancer screening test at the MedInvest Oncology Investor conference this week.
Why is ovarian cancer so hard to detect?
Advanced stage ovarian cancer has a survival rate of 17% and yet, today, there is still no screening test for the nearly 4 billion women on the planet. The reason for this is existing technologies lack the combined sensitivity and specificity to detect cancer biomarkers at very early stages when the disease is still treatable and advancement to later stages can be prevented.
Call for applications: Senior Research Associate
Join our team!
GenEndeavor is seeking individuals with strong expertise in nucleic acid testing technologies (NAT), assay development, and point-of-care diagnostics.
Successful applicants should have at least 2 years of demonstrated experience and knowledge in chemical modification of nucleic acids, lateral flow assay development, chemical ligation of oligonucleotides, and molecular biology techniques in an industry setting.
MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023
We are thrilled to announce @GenEndeavor’s participation in the upcoming MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023.
At the event, GenEndeavor will showcase our molecular diagnostics technology platform, which lowers the limit of detection of rare mutations and rapidly identifies pathogens for sensitive and real-time genetic and infectious disease detection. GenEndeavor’s current focus is to translate this new platform into an early-detection ovarian cancer screening test.
Jill Biden Announces Women's Health Research Initiative
Today First Lady Jill Biden announced an important initiative focused on womens’ health research. The announcement brings awareness to and underscores the need to bridge the gaps that exist today to finding solutions to the most significant women’s health care conditions and diseases that currently have eluded detection and treatment.
At GENENDEAVOR LLC, we are focused on developing an early-detection ovarian cancer test in an effort to, one day, make very early ovarian cancer screening possible, which today does not exist anywhere in the world. Today’s announcement is a very positive first step in the direction of enabling a potentially new generation of research initiatives that could help make ovarian cancer screening a reality.
GenEndeavor Awarded Second Phase of Prestigious NIH Grant for Development of a Rapid Airborne SARS-CoV-2 Air Monitoring System
Hayward, CA, Oct. 18, 2023 — In a critical step to improving global healthcare, GenEndeavor secured Phase 2 of the NIH Director’s Transformative Research Award. This grant supports GenEndeavor’s mission to swiftly and effectively detect airborne pathogens.
As the only independent non-academic organization to be honored with the NIH Director's Transformative Research Award, this recognition underscores our groundbreaking work in the field of molecular diagnostics and unwavering commitment to advancing and transforming healthcare solutions.